Clinical trials: Respiratory Hypersensitivity
Asthma
Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)
To evaluate the safety, tolerability and plasma levels of single oral doses of MK0633 in pediatric asthma patients ages 6 to less than 12 years.
- Trial name
- NCT00751413
- Testing
- Comparator: MK0633
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients
This is an observational retrospective analysis of linked pharmacy and medical claims data from IMS Health/Pharmetrics database.
- Trial name
- NCT01431924
- Testing
- Higher-dose inhaled corticosteroids, Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination
- Volunteers
- 7,779 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils…
- Trial name
- NCT02452190
- Testing
- Reslizumab
- Where
- 226 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Allergic Conjunctivitis, Allergic Rhinitis
Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis
Allergic conjunctivitis is one of the most common comorbidities of allergic diseases, especially of allergic rhinitis. Rhinoconjunctivitis is an allergic condition of the nasal mucosa and the eyes.
- Trial name
- NCT04532710
- Testing
- Eye Drops, Solution in Single-Dose Container
- Where
- Austria
- Volunteers
- 64 people
- Sponsor
- Marinomed Biotech AG
Asthma
A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers
GW870086X is a novel inhaled steroid that has an improved safety profile over other steroids but is also less potent. This study will look at higher doses to confirm the improved safety profile.
- Trial name
- NCT00549497
- Testing
- GW870086X
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
The primary objective is to assess whether 16 weeks of treatment with dupilumab as an adjunct to Timothy Grass Subcutaneous Immunotherapy (SCIT) improves upon the efficacy of Timothy Grass SCIT to reduce provoked allergic…
- Trial name
- NCT03558997
- Testing
- Dupilumab, Timothy Grass SCIT
- Where
- 17 sites in United States, Canada
- Volunteers
- 103 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
A Study of MRx-4DP0004 in Asthma
This is a multicentre, phase I/II, double-blind, placebo-controlled study of MRx-4DP0004 in participants taking long-term medication for asthma.
- Trial name
- NCT03851250
- Testing
- MRx-4DP0004
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- 4D pharma plc
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche
Rhinitis, Allergic, Seasonal
An Exploratory Study of PQ Grass 27600 SU
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting.
- Trial name
- NCT04687059
- Testing
- PQ Grass
- Where
- 14 sites in United States, Germany
- Volunteers
- 119 people
- Sponsor
- Allergy Therapeutics
Asthma (Diagnosis)
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for…
- Trial name
- BREADTH-EXT (NCT07677059)
- Testing
- KT-621
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 264 people
- Sponsor
- Kymera Therapeutics, Inc.
Asthma
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
Study Comparing the Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
- Trial name
- NCT03358147
- Testing
- GP MDI 28.8 μg, GP MDI 14.4 μg, GP MDI 7.2 μg
- Where
- 232 sites in United States
- Volunteers
- 1,077 people
- Sponsor
- Pearl Therapeutics, Inc.
Bronchial Asthma
Symbicort Turbuhaler 30/60 Clinical Experience Investigation
The purpose of this study is to confirm the safety (ADR related to beta stimulant drugs, unexpected ADRs) and efficacy of Symbicort in daily practice and the control status on bronchial asthma and Patient satisfaction
- Trial name
- SURE (NCT01232348)
- Where
- 47 sites in Japan
- Volunteers
- 3,643 people
- Sponsor
- AstraZeneca
Asthma
Pharmacokinetics in Adolescents
The purpose of this study is to study pharmacokinetics in adolescents.
- Trial name
- PEAK (NCT01196689)
- Testing
- AZD1981 100 mg twice daily for 61/2 days
- Where
- Sweden
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Asthma
A Study in Patients With Asthma
The purpose of the present study is to demonstrate the higher efficacy of Foster® NEXThaler® 100/6 extra fine (two inhalations b.i.d.) versus Seretide® Accuhaler® 250/50 (one inhalation b.i.d.), in terms of pulmonary function…
- Trial name
- NELSON (NCT01570478)
- Testing
- Foster® NEXThaler® 100/6 µg/unit dose, Seretide® Accuhaler® 250/50 µg/actuation
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
- Trial name
- NCT00046748
- Testing
- Omalizumab
- Volunteers
- 484 people
- Sponsor
- Novartis Pharmaceuticals
Perennial Allergic Rhinitis
A Study in Subjects With Perennial Allergic Rhinitis
The purpose of this study was to determine the efficacy and safety of the study drug compared to placebo for the treatment of subjects with perennial allergic rhinitis.
- Trial name
- NCT00210015
- Testing
- INS37217 Nasal Spray
- Volunteers
- 630 people
- Sponsor
- Merck Sharp & Dohme LLC
Rhinitis, Allergic, Seasonal
Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR
Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR
- Trial name
- NCT00521040
- Testing
- Levocetirizine dihydrochloride
- Volunteers
- 459 people
- Sponsor
- UCB Pharma
Asthma
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus
The purpose of this study is to compare the test product Salmeterol/fluticasone Easyhaler with the reference product Seretide Diskus in terms of drug absorbed in the bloodstream.
- Trial name
- NCT01766843
- Testing
- Seretide Diskus and charcoal, Seretide Diskus, SF Easyhaler and charcoal
- Where
- Finland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen
This is a Phase IIa, double blind, randomized, parallel group, placebo controlled multi centre study to evaluate the effect of AZD8154 (administered via nebulizer daily [QD]) on allergen-induced inflammation in subjects with mild…
- Trial name
- NCT04187508
- Testing
- AZD8154 nebulizer suspension, 20 mg/mL
- Where
- 5 sites in Canada
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.